HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer

被引:26
作者
Karlsen, Mona Aarenstrup [1 ,2 ]
Hogdall, Claus [2 ]
Nedergaard, Lotte [3 ]
Prahm, Kira Philipsen [1 ,2 ]
Karlsen, Nikoline Marie Schou [1 ]
Ekmann-Gade, Anne Weng [2 ]
Schnack, Tine Henrichsen [2 ]
Poulsen, Tim Svenstrup [1 ]
Christensen, Ib Jarle [1 ]
Hogdall, Estrid [1 ]
机构
[1] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Pathol, Mol Unit, Herlev Ringvej 75, DK-2730 Herlev, Denmark
[2] Univ Copenhagen, Dept Gynecol, Rigshosp, Copenhagen, Denmark
[3] Univ Copenhagen, Dept Pathol, Rigshosp, Copenhagen, Denmark
关键词
Ovarian cancer; survival; chemotherapy response; serum HE4; HE4 tissue protein expression; EPIDIDYMIS PROTEIN 4; NEOADJUVANT CHEMOTHERAPY; MALIGNANCY ALGORITHM; PROGNOSTIC-FACTOR; POOR-PROGNOSIS; CA125; SURGERY; MULTICENTER; EXPRESSION; MULTIPLE;
D O I
10.1111/apm.12625
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The aim of this study was to investigate the value of serum human epididymis protein 4 (HE4) and HE4 tissue protein expression to predict tumor resistance to adjuvant chemotherapy, progression-free survival (PFS), and overall survival in patients with epithelial ovarian cancer (EOC). Consecutive inclusion of 198 patients diagnosed with EOC was conducted. Blood samples were collected prior to surgery and tissue samples during surgery. Patient data were registered prospectively in the Danish Gynecologic Cancer Database. The association between serum HE4 and HE4 tissue protein expression, resistance to adjuvant chemotherapy, PFS, and overall survival were analyzed in univariate analyses and in multivariate analyses adjusted for age, performance score, surgical outcome, stage, grade, and histological subtype. Serum HE4 levels predicted chemotherapy resistance, PFS, and overall survival correlated significantly (p < 0.001) in the univariate analyses; but after adjustment in a multivariate model, serum HE4 was insignificant, except in a subgroup analysis of postmenopausal women, where serum HE4 significantly predicted resistance to chemotherapy and progression-free survival. HE4 tissue protein expression predicted PFS (p = 0.022) and overall survival (p = 0.047) in the univariate analysis, while HE4 tissue protein expression failed to predict these outcomes in the adjusted multivariate analyses. Serum HE4 or HE4 tissue protein expression are not independent factors of chemotherapy resistance or survival in patients with EOC, but serum HE4 might predict chemotherapy resistance and PFS in postmenopausal women.
引用
收藏
页码:1038 / 1045
页数:8
相关论文
共 29 条
[1]   Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[2]   Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? [J].
Angioli, Roberto ;
Capriglione, Stella ;
Aloisi, Alessia ;
Guzzo, Federica ;
Luvero, Daniela ;
Miranda, Andrea ;
Damiani, Patrizio ;
Montera, Roberto ;
Terranova, Corrado ;
Plotti, Francesco .
TUMOR BIOLOGY, 2014, 35 (07) :7009-7015
[3]   Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management [J].
Bandiera, Elisabetta ;
Romani, Chiara ;
Specchia, Claudia ;
Zanotti, Laura ;
Galli, Claudio ;
Ruggeri, Giuseppina ;
Tognon, Germana ;
Bignotti, Eliana ;
Tassi, Renata A. ;
Odicino, Franco ;
Caimi, Luigi ;
Sartori, Enrico ;
Santin, Alessandro D. ;
Pecorelli, Sergio ;
Ravaggi, Antonella .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2011, 20 (12) :2496-2506
[4]  
*DAN GYN CANC DAT, 2015, ANN REPORT 2014 2015
[5]   Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas [J].
Drapkin, R ;
von Horsten, HH ;
Lin, YF ;
Mok, SC ;
Crum, CP ;
Welch, WR ;
Hecht, JL .
CANCER RESEARCH, 2005, 65 (06) :2162-2169
[6]  
DUBOIS A, 2009, CANCER, V115, P1234, DOI DOI 10.1002/CNCR.24149
[7]   Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study [J].
Eisenkop, SM ;
Spirtos, NM ;
Friedman, RL ;
Lin, WCM ;
Pisani, AL ;
Perticucci, S .
GYNECOLOGIC ONCOLOGY, 2003, 90 (02) :390-396
[8]   Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study [J].
Fago-Olsen, Carsten Lindberg ;
Ottesen, Bent ;
Kehlet, Henrik ;
Antonsen, Sofie L. ;
Christensen, Ib J. ;
Markauskas, Algirdas ;
Mosgaard, Berit J. ;
Ottosen, Christian ;
Soegaard, Charlotte H. ;
Soegaard-Andersen, Erik ;
Hoegdall, Claus .
GYNECOLOGIC ONCOLOGY, 2014, 132 (02) :292-298
[9]   Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients [J].
Fanfani, F ;
Ferrandina, G ;
Corrado, G ;
Fagotti, A ;
Zakut, HV ;
Mancuso, S ;
Scambia, G .
ONCOLOGY, 2003, 65 (04) :316-322
[10]   Comprehensive analysis of HE4 expression in normal and malignant human tissues [J].
Galgano, Mary T. ;
Hampton, Garret M. ;
Frierson, Henry F., Jr. .
MODERN PATHOLOGY, 2006, 19 (06) :847-853